ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan

ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan

ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 10 mg - valsartan

ישראל - עברית - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 10 mg - valsartan

ישראל - עברית - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 5 mg - valsartan

ישראל - עברית - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 5 mg - valsartan

ישראל - עברית - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 80 mg; amlodipine as besilate 5 mg - valsartan